Price:
Rs. 10,710.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes: I0301
Frequently Asked Questions (FAQ's):
What does this test include?
This test at Metropolis Healthcare detects mutations in the BCR-ABL1 kinase domain using EDTA blood to evaluate treatment resistance in leukemia.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses IRMA (Intercalating Reporter Mutation Assay) technology to accurately identify kinase domain mutations associated with drug resistance.
Who should take this test?
Patients diagnosed with CML or Ph+ ALL who are undergoing targeted therapy or showing inadequate treatment response should consider this test at Metropolis Healthcare.
Why is this test important?
The test helps determine whether specific mutations are causing resistance to tyrosine kinase inhibitors, enabling clinicians to modify treatment based on results from Metropolis Healthcare.
Do I need any preparation before giving the sample at Metropolis Healthcare?
No fasting or special preparation is required; a routine EDTA blood sample is sufficient.
How long will it take to receive results?
Metropolis Healthcare typically provides results within several working days depending on assay complexity.
How can the results help in treatment planning?
Results from Metropolis Healthcare guide oncologists in choosing the most effective targeted therapy or adjusting existing treatment in resistant cases.
Is this test safe?
Yes, the test is safe and minimally invasive, performed through a standard blood draw by trained Metropolis Healthcare phlebotomists